

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**MEHLMAN VOGEL CASTAGNETTI INC**

2. Address:

1341 G STREET, SUITE 1100, WASHINGTON, DC 20005

3. Principal place of business (if different from line 2):

4. Contact Name: TAMIKA SPAULDING

Telephone: 2025850216

E-mail (optional): spaulding@mvc-dc.com

Senate ID #: 284950-773

House ID #:

7. Client Name:  Self

**MERCK & CO**

### TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: \_\_\_\_\_ 11. No Lobbying Activity:

### INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

#### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): 90,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): \_\_\_\_\_

#### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only  
 **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
 **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

Support reauthorization of Prescription Drug User Fee Act and Better Pharmaceuticals for Children Act (S. 1080, H.R. 2900). Support efforts to promote public/private partnerships for health technology assessment (no specific legislation). Oppose efforts to permit Rx drug importation into U.S., other than by drug's manufacturer. (No specific bill) Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill).

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BINGEL, KELLY

Covered Official Position (if applicable): N/A

Name: CASTAGNETTI, DAVID

Covered Official Position (if applicable): N/A

Name: FINLEY PICKERING, ELISE

Covered Official Position (if applicable): CHIEF OF STAFF, REP. SHADDEGG; EXEC. DIR. RPC

Name: HUDSON, KARIN

Covered Official Position (if applicable): N/A

Name: MEHLMAN, BRUCE P.

Covered Official Position (if applicable): N/A

Name: RAMPY, STACEY

Covered Official Position (if applicable): N/A

Name: ROSEN, DEAN

Covered Official Position (if applicable): HEALTH POLICY DIRECTOR, SEN. BILL FRIST

Name: THOMAS, DAVID

Covered Official Position (if applicable): CHIEF OF STAFF, REP. ZOE LOFGREN

Name: VOGEL, ALEX

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

### LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Oppose efforts to amend Medicare Modernization Act to impose government price controls on prescription drugs (H.R. 4, S. 250). Support efforts to ensure appropriate access to vaccines under Medicare Part D (no specific bill). Oppose expansion of or increase in Medicaid rebate (no specific bill).

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BINGEL, KELLY  
Covered Official Position (if applicable): N/A  
Name: CASTAGNETTI, DAVID  
Covered Official Position (if applicable): N/A  
Name: FINLEY PICKERING, ELISE  
Covered Official Position (if applicable): CHIEF OF STAFF, REP. SHADDEGG; EXEC. DIR. RPC  
Name: HUDSON, KARIN  
Covered Official Position (if applicable): N/A  
Name: MEHLMAN, BRUCE P.  
Covered Official Position (if applicable): N/A  
Name: RAMPY, STACEY  
Covered Official Position (if applicable): N/A  
Name: ROSEN, DEAN  
Covered Official Position (if applicable): HEALTH POLICY DIRECTOR, SEN. BILL FRIST  
Name: THOMAS, DAVID  
Covered Official Position (if applicable): CHIEF OF STAFF, REP. ZOE LOFGREN  
Name: VOGEL, ALEX  
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 14, 2007

Printed Name and Title: TAMIKA SPAULDING, PROJECT MANAGER -

**Information Update Page:**

**Complete ONLY where registration information has changed.**

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE      Date: Aug 14, 2007

Printed Name and Title: -